We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Offing for Teladoc Health's (TDOC) Earnings in Q1?
Read MoreHide Full Article
Teladoc Health, Inc. (TDOC - Free Report) is scheduled to release first-quarter 2021 results on Apr 28, 2021, after the market closes.
Teladoc Health’s revenues in the to-be-reported quarter are likely to have gained from growth in utilization plus a robust and growing pipeline of multi-product sales including strong demand for its whole person chronic care programs.
Continued strength in the direct-to-consumer channel, higher demand for the company’s license platform in the health system market, growth in the international markets and member additions should aid results.
Revenues from subscription access fees are likely to have increased owing to contribution from Livongo and InTouch Health, which were acquired last year. The Zacks Consensus Estimate for subscription access fee revenues is pegged at $375 million, indicating 173.8% growth from the year-ago quarter’s reported figure.
The company is also expected to have witnessed a surge in visit volumes, boosted by greater patient satisfaction as consumers benefit from the company’s convenient, lower cost and high-quality service.
Further, visits from newly-registered individuals might have shot up, indicative of more number of patients adopting the company’s virtual healthcare services. The Zacks Consensus Estimate for visit revenues is pegged at $60 million, implying 37% growth from the year-ago period’s reported figure.
Teladoc Health is likely to have witnessed growth in the international market, driven by an increased penetration in the existing geographies and its expansion into new regions.
Total expenses are likely to have escalated, primarily due to general and administrative expenses, technology and development, cost of revenues, advertising and marketing, sales, acquisition and integration.
First-Quarter Guidance
The company anticipates revenues between $445 million and $455 million while adjusted EBITDA is estimated to be $45-$48 million.
Total visits are expected in the range of 2.9-3.1 million. The company projects the total U.S. paid membership in the band of 51-52 million members. Visit-fee-only access is estimated to be available to 22-23 million individuals.
Fourth-Quarter Results
Teladoc Health incurred a loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 25 cents. Also, the reported figure was a penny wider year over year. This was primarily due to flared-up expenses.
Earnings & Revenue Expectations
The Zacks Consensus Estimate for Teladoc Health’s first-quarter loss of 59 cents per share indicates deterioration from the loss of 40 cents reported in the year-ago quarter. The consensus estimate for sales of $452.09 million suggests a 150.05% rise from the year-ago period’s reported figure.
Eanings Surprise History
The company doesn’t have an impressive earnings surprise track. Its bottom line beat estimates in just one of the last four quarters (missing the mark on the other three occasions), the average positive surprise being -2.38%. This is depicted in the chart below.
Our proven model does not predict an earnings beat for Teladoc Health this time around. The combination of a positive Earnings ESP Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But this is not the case here.
Earnings ESP: Teladoc Health has an Earnings ESP of 0.00%.
Zacks Rank: Teladoc Health currently carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Of the medical sector players that have reported first-quarter results so far, the bottom-line results of UnitedHealth Group Incorporated (UNH - Free Report) , Anthem Inc. and Tenet Healthcare Corporation (THC - Free Report) beat their respectiveZacks Consensus Estimate.
Zacks' Top Picks to Cash in on Artificial Intelligence
In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.
Image: Shutterstock
What's in Offing for Teladoc Health's (TDOC) Earnings in Q1?
Teladoc Health, Inc. (TDOC - Free Report) is scheduled to release first-quarter 2021 results on Apr 28, 2021, after the market closes.
Teladoc Health’s revenues in the to-be-reported quarter are likely to have gained from growth in utilization plus a robust and growing pipeline of multi-product sales including strong demand for its whole person chronic care programs.
Continued strength in the direct-to-consumer channel, higher demand for the company’s license platform in the health system market, growth in the international markets and member additions should aid results.
Revenues from subscription access fees are likely to have increased owing to contribution from Livongo and InTouch Health, which were acquired last year. The Zacks Consensus Estimate for subscription access fee revenues is pegged at $375 million, indicating 173.8% growth from the year-ago quarter’s reported figure.
The company is also expected to have witnessed a surge in visit volumes, boosted by greater patient satisfaction as consumers benefit from the company’s convenient, lower cost and high-quality service.
Further, visits from newly-registered individuals might have shot up, indicative of more number of patients adopting the company’s virtual healthcare services. The Zacks Consensus Estimate for visit revenues is pegged at $60 million, implying 37% growth from the year-ago period’s reported figure.
Teladoc Health is likely to have witnessed growth in the international market, driven by an increased penetration in the existing geographies and its expansion into new regions.
Total expenses are likely to have escalated, primarily due to general and administrative expenses, technology and development, cost of revenues, advertising and marketing, sales, acquisition and integration.
First-Quarter Guidance
The company anticipates revenues between $445 million and $455 million while adjusted EBITDA is estimated to be $45-$48 million.
Total visits are expected in the range of 2.9-3.1 million. The company projects the total U.S. paid membership in the band of 51-52 million members. Visit-fee-only access is estimated to be available to 22-23 million individuals.
Fourth-Quarter Results
Teladoc Health incurred a loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 25 cents. Also, the reported figure was a penny wider year over year. This was primarily due to flared-up expenses.
Earnings & Revenue Expectations
The Zacks Consensus Estimate for Teladoc Health’s first-quarter loss of 59 cents per share indicates deterioration from the loss of 40 cents reported in the year-ago quarter. The consensus estimate for sales of $452.09 million suggests a 150.05% rise from the year-ago period’s reported figure.
Eanings Surprise History
The company doesn’t have an impressive earnings surprise track. Its bottom line beat estimates in just one of the last four quarters (missing the mark on the other three occasions), the average positive surprise being -2.38%. This is depicted in the chart below.
Teladoc Health, Inc. Price and EPS Surprise
Teladoc Health, Inc. price-eps-surprise | Teladoc Health, Inc. Quote
What Our Model Says
Our proven model does not predict an earnings beat for Teladoc Health this time around. The combination of a positive Earnings ESP Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But this is not the case here.
Earnings ESP: Teladoc Health has an Earnings ESP of 0.00%.
Zacks Rank: Teladoc Health currently carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Medical Sector Releases
Of the medical sector players that have reported first-quarter results so far, the bottom-line results of UnitedHealth Group Incorporated (UNH - Free Report) , Anthem Inc. and Tenet Healthcare Corporation (THC - Free Report) beat their respectiveZacks Consensus Estimate.
Zacks' Top Picks to Cash in on Artificial Intelligence
In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.
See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>